127.02

0.66% -0.765

Abbott Laboratories (ABT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Abbott Laboratories stock is traded at $127.02, with a volume of 3.77M. It is down -0.66% in the last 24 hours and up +1.48% over the past month. Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Previous Close:

$127.78

Open:

$128.45

24h Volume:

3.77M

Relative Volume:

0.62

Market Cap:

$221.10B

Revenue:

$43.84B

Net Income/Loss:

$13.90B

P/E Ratio:

15.93

EPS:

7.9725

Net Cash Flow:

$6.92B

1W Performance:

+1.31%

1M Performance:

+1.48%

6M Performance:

-5.06%

1Y Performance:

+11.94%

1-Day Range:

$126.27

$128.60

1-Week Range:

$122.50

$129.46

52-Week Range:

$110.86

$140.84

Abbott Laboratories Stock (ABT) Company Profile

Name

Abbott Laboratories

Sector

Healthcare (1120)

Industry

Medical Devices (141)

Phone

(224) 667-6100

Address

100 ABBOTT PARK ROAD, ABBOTT PARK, IL

Employee

114,000

Twitter

@AbbottNews

Next Earnings Date

2025-10-15

Latest SEC Filings

ABT's Discussions on Twitter

Compare ABT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABT Abbott Laboratories	127.15	222.19B	43.84B	13.90B	6.92B	7.9725
BSX Boston Scientific Corp	98.55	144.97B	19.35B	2.78B	3.82B	1.8696
SYK Stryker Corp	367.60	140.12B	24.38B	2.94B	4.07B	7.6159
MDT Medtronic Plc	99.74	128.60B	34.76B	4.79B	5.21B	3.7017
EW Edwards Lifesciences Corp	84.61	49.82B	5.88B	1.34B	799.60M	2.3489

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-25	Initiated	The Benchmark Company	Buy
Jul-18-25	Upgrade	Jefferies	Hold → Buy
Jun-16-25	Initiated	Leerink Partners	Market Perform
Oct-08-24	Initiated	Oppenheimer	Outperform
Sep-19-24	Initiated	Piper Sandler	Overweight
Jul-30-24	Downgrade	Edward Jones	Buy → Hold
May-30-24	Initiated	Goldman	Buy
Jul-21-23	Upgrade	Wolfe Research	Underperform → Peer Perform
May-30-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-20-23	Reiterated	Barclays	Overweight
Apr-20-23	Reiterated	Bernstein	Outperform
Apr-20-23	Reiterated	JP Morgan	Overweight
Apr-20-23	Reiterated	Raymond James	Outperform
Apr-20-23	Reiterated	UBS	Buy
Apr-20-23	Reiterated	Wolfe Research	Underperform
Mar-29-23	Initiated	UBS	Buy
Oct-26-22	Initiated	Mizuho	Neutral
Oct-18-22	Initiated	Barclays	Overweight
Oct-12-22	Initiated	Jefferies	Hold
Jul-06-22	Initiated	Wolfe Research	Underperform
Mar-02-22	Resumed	BofA Securities	Buy
Jan-27-22	Reiterated	Credit Suisse	Outperform
Jan-27-22	Reiterated	Morgan Stanley	Overweight
Jan-27-22	Reiterated	Raymond James	Outperform
Jan-27-22	Reiterated	UBS	Buy
Dec-10-21	Initiated	RBC Capital Mkts	Outperform
Oct-27-21	Upgrade	Atlantic Equities	Neutral → Overweight
Oct-14-21	Initiated	Redburn	Neutral
May-25-21	Initiated	Barclays	Overweight
Apr-15-21	Initiated	Atlantic Equities	Neutral
Jan-28-21	Upgrade	BTIG Research	Neutral → Buy
Sep-11-20	Initiated	Wolfe Research	Outperform
Jun-01-20	Downgrade	Goldman	Neutral → Sell
Mar-05-20	Initiated	Citigroup	Buy
Feb-13-20	Initiated	Goldman	Neutral
Feb-06-20	Resumed	BTIG Research	Neutral
Jan-02-20	Downgrade	Guggenheim	Buy → Neutral
Jun-13-19	Reiterated	BofA/Merrill	Buy
Feb-07-19	Reiterated	BofA/Merrill	Buy
Jan-02-19	Downgrade	Citigroup	Neutral → Sell
Nov-30-18	Upgrade	Goldman	Neutral → Buy
Oct-16-18	Initiated	Barclays	Overweight
Jun-27-18	Initiated	Bernstein	Outperform
Jan-30-18	Reiterated	Citigroup	Neutral
Jan-25-18	Reiterated	Stifel	Buy
Jan-25-18	Upgrade	William Blair	Mkt Perform → Outperform
Jan-03-18	Initiated	Evercore ISI	Outperform
Jan-02-18	Upgrade	JP Morgan	Neutral → Overweight
Jan-02-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-19-17	Reiterated	RBC Capital Mkts	Outperform
Oct-19-17	Reiterated	Stifel	Buy

View All

Abbott Laboratories Stock (ABT) Latest News

01:25 AM

Is Abbott Laboratories (ABT) Pricing Look Attractive After Recent Steady Multi‑Year Returns - simplywall.st

01:25 AM

12:13 PM

17-year Abbott employee sues, alleges firing over approved FMLA use - HRD America

12:13 PM

09:17 AM

Abbott: Not Cheap, But Built To Compound In Uncertain Markets (NYSE:ABT) - Seeking Alpha

09:17 AM

08:34 AM

Sentinel Opportunity Fund I Closes Seventh and Eighth Acquisitions with Abbott Laboratories and V3 Engineering, Advancing a Diversified Portfolio Strategy - The Globe and Mail

08:34 AM

05:11 AM

Abbott’s $105 Bid Put Exact Sciences Back In Play - Finimize

05:11 AM

Jan 06, 2026

Abbott’s New Libre Assist AI Tool Might Change The Case For Investing In Abbott Laboratories (ABT) - simplywall.st

Jan 06, 2026

Abbott Laboratories (NYSE:ABT) Given New $144.00 Price Target at Evercore ISI - MarketBeat

Jan 06, 2026

Should Abbott’s AI-Powered Libre Assist Shift Its Diabetes Platform Strategy Narrative for ABT Investors? - Yahoo Finance

Jan 06, 2026

Hematology Market Booming with Rapid Growth Through 2033 | - openPR.com

Jan 06, 2026